NEXUS SURGICAL AND MEDICARE LI (NEXUSSURGL.BO)
INR 22.99
(1.37%)
INR 22.99
(1.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.98 Million INR | 35.27% |
| 2022 | 2.31 Million INR | -40.98% |
| 2021 | 3.69 Million INR | 124.1% |
| 2020 | 1.64 Million INR | 125.21% |
| 2019 | -52.76 Million INR | 140.65% |
| 2018 | -1.03 Million INR | 52.79% |
| 2017 | -3.17 Million INR | -110.34% |
| 2016 | -1.81 Million INR | -323.24% |
| 2015 | 812.12 Thousand INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.21 Million INR | 44.91% |
| 2023 Q4 | 881 Thousand INR | 53.75% |
| 2023 Q1 | 288 Thousand INR | 121.83% |
| 2023 FY | - INR | 35.27% |
| 2023 Q2 | 916 Thousand INR | 218.06% |
| 2023 Q3 | 573 Thousand INR | -37.45% |
| 2022 Q2 | -1.83 Million INR | -152.36% |
| 2022 FY | - INR | -40.98% |
| 2022 Q4 | -1.31 Million INR | -172.83% |
| 2022 Q3 | 1.81 Million INR | 198.48% |
| 2022 Q1 | 3.51 Million INR | 161.0% |
| 2021 Q1 | 1.46 Million INR | 149.31% |
| 2021 Q4 | -5.75 Million INR | -196.56% |
| 2021 FY | - INR | 124.1% |
| 2021 Q3 | 5.96 Million INR | 196.47% |
| 2021 Q2 | 2.01 Million INR | 37.18% |
| 2020 FY | - INR | 125.21% |
| 2020 Q4 | -2.97 Million INR | 0.0% |
| 2019 FY | - INR | 140.65% |
| 2018 FY | - INR | 52.79% |
| 2017 FY | - INR | -110.34% |
| 2016 FY | - INR | -323.24% |
| 2015 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Chandra Bhagat Pharma Limited | 36.55 Million INR | 91.843% |
| Checkpoint Trends Limited | 297.07 Thousand INR | -903.783% |
| Everest Organics Limited | 118.72 Million INR | 97.488% |
| GUJARAT INJECT (KERALA) LTD. | 1.05 Million INR | -183.285% |
| NATURO INDIABULL LIMITED | 14.68 Million INR | 79.697% |
| Rajnish Wellness Limited | 19.93 Million INR | 85.045% |
| Rama Vision Limited | 67.79 Million INR | 95.601% |
| Vivo Bio Tech Limited | 212.99 Million INR | 98.6% |